Forecast
The analysts' average price target is €27.34 (+1,029.75%). The median is €27.34 (+1,029.75%).
| Buy |
Â
2 |
| Hold |
Â
4 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last year, Kinnate Biopharma had revenue of €0 and net profit of -€101.9M
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -722.78K | 28.36% |
| Net profit | -101.9M | 4.13% |
| EBITDA | -106.93M | 2.73% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €113.91M |
Number of shares | 47.17M |
52-week high/low | €6.55 - €0.95 |
| Dividends | No |
Beta | 1.34 |
P/E ratio | -1.10 |
PEG ratio | -0.16 |
P/B ratio | 0.77 |
P/S ratio | 0.00 |
Company profile
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
| Name | Kinnate Biopharma |
| CEO | Nima Farzan |
| Headquarters | San Francisco,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 12/03/2020 |
| Employees | 84 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | KNTE |